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Abstract
Background: Marfan syndrome (MFS) is a pleiotropic genetic disorder with major features in cardiovascular, ocular and
skeletal systems, associated with large clinical variability. Numerous studies reveal an involvement of TGF-b signaling.
However, the contribution of tissue inflammation is not addressed so far.
Methodology/Principal Findings: Here we showed that both TGF-b and inflammation are up-regulated in patients with
MFS. We analyzed transcriptome-wide gene expression in 55 MFS patients using Affymetrix Human Exon 1.0 ST Array and
levels of TGF-b and various cytokines in their plasma. Within our MFS population, increased plasma levels of TGF-b were
found especially in MFS patients with aortic root dilatation (124 pg/ml), when compared to MFS patients with normal aorta
(10 pg/ml; p = 861026, 95% CI: 70–159 pg/ml). Interestingly, our microarray data show that increased expression of
inflammatory genes was associated with major clinical features within the MFS patients group; namely severity of the aortic
root dilatation (HLA-DRB1 and HLA-DRB5 genes; r = 0.56 for both; False Discovery Rate(FDR) = 0%), ocular lens dislocation
(RAET1L, CCL19 and HLA-DQB2; Fold Change (FC) = 1.8; 1.4; 1.5, FDR= 0%) and specific skeletal features (HLA-DRB1, HLA-
DRB5, GZMK; FC = 8.8, 7.1, 1.3; FDR= 0%). Patients with progressive aortic disease had higher levels of Macrophage Colony
Stimulating Factor (M-CSF) in blood. When comparing MFS aortic root vessel wall with non-MFS aortic root, increased
numbers of CD4+ T-cells were found in the media (p = 0.02) and increased number of CD8+ T-cells (p = 0.003) in the
adventitia of the MFS patients.
Conclusion/Significance: In conclusion, our results imply a modifying role of inflammation in MFS. Inflammation might be a
novel therapeutic target in these patients.
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Introduction
Marfan syndrome (MFS) is an autosomal dominant connective
tissue disorder with a systemic involvement. Main clinical features
are aortic root dilatation, ocular lens dislocation and typical skeletal
features resulting from overgrowth of long bones. Other organ
systems like lungs, dura and in tegmentum are also often affected. It
has an incidence of approximately 1 in 5,000 and is probably the
most common monogenetic connective tissue disorder [1].
MFS is caused by mutations in the fibrillin-1 gene (FBN1, MIM
134797) coding for the fibillin-1 protein, which is an abundant
component of the extracellular matrix throughout all organ-
systems [2,3]. It has been thought that structural weakness of the
connective tissue due to a defect fibrillin-1 protein leads to its
clinical manifestations. Recently, evidence emerged about the role
of altered Transforming Growth Factor-b (TGF-b) signaling in
MFS pathogenesis. The extracellular matrix was found to regulate
activation and bioavailability of TGF-b [4]. Due to a defect or
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deficient fibrillin-1, enhanced release and activation of TGF-b
occurs in the extracellular matrix. Both Smad-dependent and non-
canonical (ERK dependent) TGF-b signaling contribute to the
development of aortic root aneurysm in mouse model of MFS
[5,6]. TGF-b blockade by anti-TGF-b antibodies reduced the
aortic root dilatation and myopathy in a mouse model of MFS
[7,8].
Interestingly, losartan, a commonly used anti-hypertensive drug
with angiotensin (Ang) II blocking effects, had the same effect as
anti-TGF-b antibodies, which offers novel treatment possibilities
[7–9]. Losartan blocks selectively the angiotensine type 1 (AT1)
receptor, allowing the protective angiotensine type 2 (AT2)
receptor signaling in Marfan mice [5]. Apart from its role in
hypertension, Ang II is a well known pro-inflammatory peptide
that effects the cardiovascular system and can even induce aortic
aneurysm formation (predominantly in the descending aorta) in
mice. TGF-b activity, however, protects against inflammatory
aneurysm progression in the murine AngII-induced aneurysm
model, which is contradictory to the pathogenic role of TGF-b in
MFS [10]. This reflects the complexity of the relation of TGF-b
signaling and inflammation during aortic dilatation, which
remains elusive in MFS.
Apart from losartan, there are more indications that inflamma-
tion plays a role in aortic root dilatation in the Marfan mouse
model. Aortic wall extracts of Marfan mice induced increased
chemotaxis of macrophages in vitro, mainly induced by elastin
binding protein, showing a chemotactic stimulatory activity of
fibrillin-1fragments [11]. These results were recently confirmed in
MFS patients’ aortas.[12] Furthermore, macrophages found in the
aortic wall of these mice are positive for certain matrix
metalloproteinases, which are enzymes that contribute to the
degradation of the extracellular matrix. Doxycycline, a nonspecific
inhibitor of matrix metalloproteinases, ameliorated aortic dilata-
tion, improved elastic fiber organization and reduced TGF-b
signaling in MFS mice. This suggests that macrophage activation
contributes to the microfibril reduction and subsequent aortic
dilatation. In addition, in patients with MFS increased counts of
inflammatory cells were found in the media of the aortic wall when
compared with non-MFS controls, suggesting that an inflamma-
tory process could enhance disease progression [13].
MFS is a pleiotropic disorder with large clinical and genetic
variability both between and within MFS families [14,15]. The
variable and unpredictable clinical course of the disease hampers
clinical management and counseling of these patients. In this
transcriptome wide gene expression study, we investigated the role
of TGF-b and inflammation related genes within a group of MFS
patients, to elucidate if these pathways are correlated to MFS
severity or specific MFS clinical features.
Results
Microarray analysis was performed with fresh frozen skin
biopsies of 55 MFS patients, using Affymetrix Human Exon 1.0
ST Arrays (approximately 17,800 genes). Patients’ characteristics
are presented in Table 1. Skin was used as a model of the
connective tissue, because of the presence of myofibroblasts that
produce extracellular matrix proteins in the most voluminous part
of connective tissue in our body, namely the skin-dermis.
Upon transcriptome wide gene expression analysis, patients
were clustered based on gene expression profiles using hierarchical
clustering. This analysis revealed four distinct patient clusters.
(Figure S1). However, disease severity did not differ between the
patients clusters (data not shown). This implies that there is no
uniform gene expression pattern in the connective tissue of the skin
that can predict disease severity or a pattern of clinical MFS
features. Gene expression may not be regulated in a patient
specific manner, but possibly in an organ specific manner. To test
this, we investigated whether different features co-segregated in
same patients and found low correlations (r = 0–0.3, data not
shown). This supports the hypothesis that the pathogenesis of
different phenotypes in MFS is most probably organ specific. In
order to identify genes and pathways contributing to the
pathogenesis of different clinical features of MFS (concerning
specific organ-systems), we compared gene expression profiles per
MFS feature within the MFS patient group, where different
patients show different MFS features, as listed in Table 1.
Aortic root dilatation is associated with increased
expression of inflammatory genes and enhanced TGF-b
levels in blood
Gene expression was first compared between MFS patients with
and without aortic root dilatation. It revealed one significantly
down-regulated gene in patients with aortic root dilatation:
MEGF8 (Multiple Epidermal Growth Factor-like-domains 8)
(FDR=0%, FC=0.62) (Figure 1).
Next, we studied gene expression in the subpopulation of MFS
patients who are monitored in time for aortic root dilatation.
Aortic phenotype was first analyzed as aortic root dilatation rate
(mm/yr) in non-operated patients, which reflects the progressive-
ness of the disease. Strikingly, patients with progressive aortic root
dilatation (mean aortic dilatation rate of 0.9 mm/year) had an
increased expression of HLA-DRB1 and HLA-DRB5 genes (r = 0.56
for both; FDR=0%) (Figure 2) when compared to the patients
with low aortic root dilatation rate (mean aortic dilatation rate of
Table 1. Patients characteristics.
Features A 55 MFS Patients
Age,y, mean (range) 36 (18–62)
Sex (male/female) 33/22
Cardiovascular features
Aortic root dilatationB 47 (85)
Mean aortic root dilatation rate (SD) 0.46 (0.4)
Mitral valve prolapse 25 (45)
Ocular lens dislocations 32 (58)
Skeletal features
Pectus deformity 33 (60)
severe excavatum 10 (18)
mild excavatum 7 (12)
carinatum 16 (30)
Reduced elbow extension 9 (16)
Joints hypermobility 14 (25)
Severe scoliosis 15 (27)
Hindfoot deformity 26 (47)
Wrist and thumb sign 37 (60)
Other MFS features
Dural ectasia 21 (38)
Pneumothorax/apical blebs 11 (20)
AData are shown in patient numbers (percentage) if not otherwise indicated.
BOf these patients 18 had aortic root replacement and two had dilatation of
descending aorta.
doi:10.1371/journal.pone.0032963.t001
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0.1 mm/yr). These two genes code for the heavy chain of the
MHC II, which mediates activation of T helper cells during an
adaptive immune response. Up-regulation of these genes indicates
an increased inflammatory response in patients with progressive
aortic disease compared to patients with mild aortic disease.
Interestingly, whereas the expression of a growth related gene was
down-regulated when comparing MFS with versus without aortic
dilatation, expression of inflammatory genes was up-regulated in
patients with progressive aortic disease.
We further compared inflammatory cell-profiles in aortic
surgical specimens of 11 MFS patients after aortic root
replacement with 6 control aortic root specimens of patients with
Marfan-unrelated aortic pathology. Immunohistochemistry was
performed using well-established markers of macrophages, T-
helper cells and cytotoxic T-cells (CD68+, CD4+ and CD8+,
respectively). Aortic media and adventitia were analyzed sepa-
rately. Histological analysis of Marfan patients’ aortic media
revealed cystic media necrosis with increased macrophage counts,
although not significantly (p = 0.16) (Figure 3A). CD4+T helper
cell counts were significantly increased (p = 0.02), whereas the
counts of cytotoxic T-cells did not differ between the groups in the
aortic media (2 cells/field +/22; p = 0.4). In the adventitia,
however, we found increased counts of cytotoxic T-cells
(p = 0.003) (Figure 3A) and no difference in the counts of other
cell-types (CD68: 24 cells/field +/210, p = 0.8; CD4: 18 cells/
field +/213, p = 1). Both in aortic media and adventitia,
inflammatory cells segregated along the media/adventitia border
(Figure 3B).
Similarly, we investigated whether TGF-b or inflammatory
markers in blood would correlate to aortic phenotype in MFS
patients. TGF-b, C-Reactive Protein (CRP; a well established
aspecific marker of systemic inflammation) and several prominent
cytokines were measured in plasma of our MFS patient group
(Table S1). The tested cytokines are pro- or anti-inflammatory in
nature and can be produced by activated tissue cells and
inflammatory cells during an inflammatory response, causing
growth/differentiation and chemoattraction [16]. The average
levels of a large number of cytokines was barely detectable (namely
IL-1b, IL-2, IL-4, IL-6, IL-10 and TNFa). Certain cytokines had
substantially detectable levels in plasma (for example IL-8, IL-17,
IL-18, IFN-c and MCP-1) in a number of patients, however we
could not correlate these high levels in these patients to specific
MFS features. Interestingly MFS patients with aortic root
dilatation had a 10-fold higher level of TGF-b (125 pg/ml) when
compared to the patients without aortic root dilatation
(p = 861026) (Figure 4A). Yet, TGF-b levels did neither correlate
with the aortic root diameter when corrected for age, sex and BSA
(Z-score of the aortic root), nor with the progressiveness of the
aortic dilatation rate (p = 0.2 and p=1, respectively) (Figure S2A
and Figure S2B). In MFS patients, CRP levels were not elevated
(Table S1). CRP levels in the normal range (,5 mg/L) are known
to be predictive of atherosclerosis-related cardiovascular events
such as myocardial infarction or stroke, with moderate risk at
levels .1 mg/L and high risk at levels .3 mg/L. CRP levels,
however, did not correlate with any features investigated. Of all
inflammatory cytokines measured, only Macrophage-Colony
Stimulating Factor (M-CSF) correlated with a specific MFS
feature, namely progressive aortic root dilatation. Patients with a
dilatation rate of 0.9 mm/year had 2-fold higher levels of M-CSF
in plasma (1 pg/ml, p = 0.05) when compared with patients with
mild aortic disease with an aortic dilatation rate of 0.1 mm/year
(Figure 4b). Therefore, the progression of the disease correlated
with a potent macrophage attractant, namely M-CSF. Together,
these findings point to the role of an increased TGF-b signaling in
initiating aortic dilatation, whereas the severity of disease
progression seems to be defined by an inflammatory response.
Figure 1. In patients with aortic root dilatation MEGF8 was
found relatively down-regulated (FDR=0%, FC=0.62). MEGF8
contains multiple EGF-like domains which are believed to play an
important role in cell-adhesion and receptor-ligand interactions.
doi:10.1371/journal.pone.0032963.g001
Figure 2. Differences in aortic root dilatation rates measured over a period of 3–12 years between patients with low (0.1 mm/yr)
and high (0.9 mm/yr) gene expressions of HLA-DRB1 and HLA-DRB5 genes.
doi:10.1371/journal.pone.0032963.g002
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Other features of MFS are associated with inflammation
We further investigated whether inflammation contributes to
the pathogenesis of other Marfan features, such as ocular lens
dislocation and skeletal features.
Ocular lens dislocation. Analysis of differences in gene
expression between the patients with ocular lens dislocation and
those without ocular lens dislocation revealed eight differentially
expressed genes (FDR=0%) (Table S2). Interestingly, three of
these genes were involved in inflammatory pathways, specifically
RAET1L, CCL19 and HLA-DQB2 (Figure 5). These genes were all
up-regulated in MFS patients with ocular lens dislocation.
RAETL1 is a member of the MHC I complex family and it
activates Natural Killer (NK) cells and T cells. CCL19 encodes for
the MIP-3b cytokine, which is involved in lymphocyte homing and
Figure 3. Inflammatory cells present in the aortic root vessel wall. (A) Increased cell counts of macrophages (CD68+) and T helper cells
(CD4+) were found in the aortic media of MFS patients when compared to 6 non-Marfan controls. In adventitia, however, we found increased
numbers of cytotoxic T cells (CD8+). (B) In the media, the inflammatory cells were segregating around fields of cystic media necrosis (arrows),
predominantly along the adventitial side of aortic wall, in MFS patients. In the adventitia, the CD8+ T-cells showed the same segregation pattern
along the media-adventitia border. M- aortic media; A- aortic adventitia.
doi:10.1371/journal.pone.0032963.g003
Figure 4. Cytokines in plasma from MFS patients. (A) In patients with aortic root dilatation strikingly higher levels of TGF-b were found
(p = 861026), when compared to the patients without aortic root dilatation. (B) The progression of the aortic disease was reflected by the levels of M-
CSF. Patients with progressive aortic root dilatation (aortic dilatation rate of 0.9 mm/year) had higher levels of Macrophage-Colony Stimulating Factor
(M-CSF) in plasma (p = 0.05) when compared to patients with mild aortic disease (aortic dilatation rate of 0.1 mm/y).
doi:10.1371/journal.pone.0032963.g004
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migration. HLA-DQB2 encodes for the heavy b chain of the
antigen presenting MHC II complex. They are members of both
the innate and the adaptive inflammatory pathways.
Skeletal features. Furthermore, skeletal features were
analyzed. In patients with elbow contractures and scoliosis
(sideways curving of the spine), an up-regulation of three
inflammatory genes was found when compared with patients
without those features, namely HLA-DRB1 and HLA-DRB5,
(FC=8.8, 7.1), and GZMK (FC= 1.3; FDR=0%) (Figure 6).
The same HLA-DRB genes were also increased in the MFS
patients with enhanced aortic dilatation rates. HLA-DRB proteins
are involved in MHC-II activation of T-helper cells, while GMZK
encodes for granzyme K, a cytokine produced by cytotoxic T cells.
Cytotoxic T cells were also found to be increased in the adventitia
of the MFS aortic vessel wall. The appearance of inflammatory
genes in multiple features of MFS strengthens our view that
inflammation can play an important role in MFS.
Interestingly, in patients with chest deformities resulting from
the over-growth of ribs, we found a predominant up-regulation of
growth-related genes. Expression profiles of patients carrying
pectus deformities (severe pectus excavatum and pectus carinatum)
were compared with patients without these features. Multiclass
analysis of these deformities revealed 40 differentially expressed
genes with FDR=0% between the groups. (Table S3 for up-
regulated genes and Table S4 for down-regulated genes). Some of
these genes are known TGF-b related genes (FLRT3, WISP2,
CLK1, ACVRL1 and IGFBP4). In addition, six inflammatory
genes were present in the list of differentially expressed genes,
namely CD68, CD13, CD248, CD24, CD81 and SOD3 (Figure 7).
The CD molecules are cell surface molecules participating in pro-
inflammatory cell interactions. SOD3 encodes for extracellular
superoxide dismutase, which is an enzyme that protects against
oxidative stress caused by inflammatory cells. (FC= 0.6, 0.8; 0.6;
0.6; 1.6; 0.6 respectively; FDR=0%). Five of these inflammatory
genes were down-regulated in patients with chest deformities when
compared to patients without these features. Only CD24 was
increased in this subpopulation of MFS patients. CD24 is known
to selectively repress tissue damage-induced immune responses
[17] and in that light high CD24 is anti-inflammatory.
When looking at a relationship between blood TGF-b levels and
chest deformities, no significant correlation was found, even
though genes related to TGF-b signaling are differentially
regulated strongly in this MFS feature.
MFS patients with other skeletal features, mitral valve prolapse,
dural ectasia and pneumothorax revealed no gene expression
differences when comparing them to MFS patients without these
specific features.
Discussion
In this study we demonstrate that, next to the established role of
TGF-b, there is an association of increased expression of
inflammatory genes with aortic root dilatation, ocular lens
dislocation and most skeletal features in MFS. Our results
introduce a potential aggravating role of inflammation in disease
severity which seems to be ‘‘on top of’’ disturbed TGF-b signaling.
All Marfan features develop during the postnatal life, they are
age dependent and accompanied by microfibril-reduction on the
molecular level. Low-grade inflammation may contribute to this
process. It is known that some of these features, like the elbow
contractures and spine deformities, can be seen in other
inflammatory and auto-immune diseases, such as rheumatoid
arthritis and ankylosing spondylitis. Whereas many MFS features
showed and increased inflammatory profile, only chest deformities
resulting from overgrowth of the ribs showed a reduced
inflammatory response and increased TGF-b signaling on a gene
expression level.
On protein level, TGF-b plasma values were highly increased in
MFS patients with aortic root dilatation. On gene expression level,
decreased expression of MEGF8 gene was found in MFS patients
with aortic root dilatation. Although there is little known about the
function of this gene, it contains multiple EGF-like domains like
FBN1 gene which are believed to play an important role in cell-
adhesion and receptor-ligand interactions. Recently, mutations in
this gene were found to result in extensive cardiac malformations
in mice and zebrafish (heterotaxy) indicating that this gene is
important for normal development of the cardiovascular system
[18]. Aortic disease is the main clinical problem in MFS patients
and defines the morbidity and the mortality in this patient group.
Strikingly, the high levels of TGF-b in blood showed no
correlation with the progressiveness of the aortic disease.
Inflammation, however, did correlate with progression measured
in time as the aortic root dilatation rate. The discrete ‘‘on-top-of
disturbed TGF-b signaling’’ contribution of inflammation in the
disease pathogenesis might be the reason that MFS was never seen
as an inflammatory disease. Now it seems that TGF-b levels in
blood could possibly function as a biomarker to predict the onset
of an aortic phenotype. In addition, when MFS patients have been
diagnosed with aortic root dilatation, increased blood M-CSF
levels can indicate the aggressiveness of the aortic disease in order
to differentiate MFS patients needing frequent or less frequent
follow-up of aortic root diameters. With the knowledge that
inflammation plays a key role in the aortic root dilatation rate, an
active search can be started to find even stronger biomarkers for
disease progression.
Figure 5. Inflammatory genes significantly up-regulated in patients with ocular lens dislocation. RAETL1 is a member of the MHC I
complex, it activates NK and T cells via NKG2D ligand. CCL19 codes for the MIP-3b cytokine which is involved in normal lymphocyte homing and
migration. HLA-DQB2 codes for the heavy b chain of the antigen presenting MHC II complex. (FC= 1.8; 1.4; 1.5 respectively, FDR= 0%).
doi:10.1371/journal.pone.0032963.g005
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On gene expression level, expression levels of HLA-DRB1 and
HLA-DRB5 genes in the skin could distinguish between patients
with mild aortic disease and those with progressive aortic disease.
Interestingly, HLA-DRB1 polymorphisms are linked to chronic
periaortitis patients (with incidence of aneurysm development) and
abdominal aortic aneurysm patients [19–22], suggesting these
genes have significance in aortic aneurysm formation. SNP
analysis of these polymorphisms in large groups of MFS patients
may therefore be informative as to which MFS patient is
susceptible to develop progressive aortic root dilatation (or elbow
contractures).
Our data indicate that inflammatory responses contribute
particularly to aortic disease progression and may independently
explain the large clinical variability seen in patients carrying even
the same FBN1 gene mutation. Along this line, the aortic root
phenotype was clearly improved in Marfan mice when the drugs
with additional anti-inflammatory properties (losartan [23,24] or
doxycyclin [25–27]) were administered. Even less MFS manifes-
tation was observed when both drugs were given simultaneously,
indicating different inflammatory pathways involved in aortic root
dilatation (19). The improved MFS phenotype with anti-
inflammatory drugs was established in the background of TGF-b
Figure 6. Inflammatory genes up-regulated in patients with reduced elbow extension and scoliosis. HLA-DRB1 and HLA-DRB5 genes
code for the heavy chain of the MHC II and are involved in antigen presenting. GZMK gene codes for granzyme K, produced by cytotoxic T-cells and
NK cells which induces apoptosis. (FC = 8.8, 7.1 and 1.3 respectively, FDR= 0%).
doi:10.1371/journal.pone.0032963.g006
Figure 7. Six inflammatory genes differentially expressed in patients with pectus deformities, of which five are down-regulated. The
CD molecules are cell surface molecules participating in inflammatory cell interactions. SOD3 encodes for extracellular superoxide dismutase, which is
an enzyme that protects against oxidative stress caused by inflammatory cells. (FC = 0.6, 0.8; 0.6; 1.6; 0.6; 0.6respectively; FDR= 0%).
doi:10.1371/journal.pone.0032963.g007
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signaling in these mice, which should thus also be feasible in
human MFS patients in future.
Historically, aortic disease in MFS is considered a disease of the
aortic media, where we indeed find medial necrosis and
inflammatory cells. However, our histological results also show
significantly increased counts of CD8+ T-cells in the Marfan
aortas, emphasizing a role for the aortic adventitia. In line with
these data, Lindeman and co-workers found that collagen
microarchitecture in the aortic adventitia of MFS patients was
impaired, whereas the medial layer is relatively intact when it
comes to endurance of pressure [28]. Basically, the adventitia
serves as an ‘‘external stent’’ determining maximal diameter of the
vessel. When its structure is impaired its ‘‘stent’’ function is lost.
The authors also showed that fibrillin-1 is more abundantly
present in the adventitia of healthy control tissue (where it is
associated to collagen fibers), rather than in the media of the aortic
wall (20). Therefore, it seems that FBN1 mutations could easily
affect the organization of the collagen fibers in the aortic
adventitia. TGF-b signaling is known to enhance collagen
production, however, the quality of the collagen triple helix and
the network of fibers formed is presumably more important that
the amount of collagen alone. Defective fibrillin-1 in MFS
apparently leads to an impaired collagen fiber/network organiza-
tion. Aortic damage due to impaired resistance to pressure may
cause collagen damage, and collagen degradation products
resulting from this process may induce inflammation. The
susceptibility of certain MFS patients to develop aortic inflamma-
tion remains to be elucidated.
The main limitation of this study is its correlational character, as
biological material obtained allowed no functional studies. Our
work provided interesting directions for future comprehensive
research on interactions of TGF-b and inflammatory pathways.
In conclusion, the most prominent finding of this paper is a
simultaneous increase of TGF-b and inflammation in aortic
dilatation in Marfan syndrome, with TGF-b being predictive for
aortic dilatation and inflammation being correlated to the
progression of aortic root dilatation. In addition, we presented
evidence of inflammatory contribution in the development of
many of the other clinical features of MFS, with the exception of
chest deformities. These findings open novel possibilities for anti-
inflammatory treatment strategies in Marfan patients to reduce
MFS severity.
Methods
Study subjects, phenotype and biological material
Patients were adult patients with an established diagnosis of
MFS according to the Ghent criteria, participating in the
COMPARE study [29]. All the analyses presented in this study
were performed in the biological material collected at the study
inclusion, prior to losartan initiation. The COMPARE study is a
randomized clinical trial investigating effects of losartan on a wide
range of clinical and molecular parameters in MFS patients.
Phenotypic features were scored at the inclusion in the
COMPARE study by two investigators as indicated for the
diagnosis of the MFS according to the Ghent criteria [30]. Aortic
root dilatation was assessed by means of cardiac Magentic
Resonance (cMRI) as described earlier [31]. Aortic root dilatation
rate (mm/y) was derived first in a discovery set of 20 patients in
whom aortic root dilatation rate was available from a period of 12
years of follow-up with cMRI. In additional 13 patients aortic root
dilatation rate was derived from clinical cMRI scans over a period
of at least 3 years. Punch skin biopsies were taken from the upper
thigh of consenting patients and immediately snap-frozen.
Biological material sampling and the trial were conducted with
approval from institutional review boards in four participating
academic hospitals in the The Netherlands (Academic Medical
Centre Amsterdam; Radboud University Nijmegen Medical
Centre; Leiden University Medical Centre; University Medical
Centre Groningen). Written informed consent was obtained from
all participants.
RNA isolation
Full skin punch biopsies of 4 mm (,5–15 mg) were used to
isolate total RNA. Skin biopsies were pulverized in liquid nitrogen
and transferred to 1.5 ml tubes containing Qiazol (Qiagen). Crude
RNA extractions were obtained according to manufacturer’s
instructions with the addition of Phase-Lock Gel Heavy (5 Prime)
to obtain a better phase separation. The crude RNA fractions were
further purified with the RNeasy Minelute Cleanup Kit (Qiagen)
according to Appendix D protocol: RNA Cleanup after Lysis and
Homogenization with QIAzol Lysis Reagent. RNA yield was
measured on a Nanodrop ND-1000 (Thermo Fisher Scientific)
and the RNA quality was investigated on the BioAnalyzer 2100
(Agilent Technologies) with the RNA 6000 Pico Chip Kit (Agilent
Technologies). Only RNA samples with sufficient yield and RIN-
values above 6.5 were used for analysis.
Microarrays
Gene expression was analyzed with Affymetric Human Exon
1.0 ST Arrays in 55 patients. Sense-strand cDNA was generated
from total RNA using Ambion WT Expression Kit (Applied
Biosystems) conform manufacturer’s instructions. Further steps
were performed using manufacturer’s protocols for the GeneChip
platform (Affymetrix). Those included purification of double-
stranded cDNA, synthesis of cRNA by in vitro transcription,
recovery and quantitation of biotin-labeled cRNA, fragmentation
of this cRNA and subsequent hybridization to the microarray
slide, posthybridization washings and detection of the hybridized
cRNA using a streptavidin-coupled fluorescent dye. Hybridized
Affymetrix Arrays were scanned using Gene-Chip Scanner 3000-
7G (Affymetrix). Image generation and feature extraction were
performed using Affymetrix GCOS Software v1.4.0.036.
TGF-b and cytokine measurements
Cytokines and TGF-b were assessed in EDTA plasma samples.
Total TGF-b1, i.e. latent and active TGF-b, was determined with
an ELISA using commercially available kit (Bio-Rad, Richmond,
CA). The neo-epitope in active TGF-b that is recognized by the
antibody pair is induced in latent TGF-b1 by acid-activation (with
1N HCl). Inflammatory mediators were measured using the
custom suspension bead assays (Bio-Rad, Richmond, CA) using a
Luminex reader.
Immunohistochemistry of aortic specimen
Aortic tissue of MFS patients was collected from operated
patients in the period of 2008–2010 and was immediately
formalin-fixated. Aortic tissue of six control patients was gathered
from the pathology records of AMC Amsterdam. Primary aortic
pathology in six control aortic samples (age range 21–68 years) was
unrelated to MFS: four of controls were surgical specimen and two
were autopsy material. Autopsy specimens were from two patients
who died from subarachnoidal bleeding and myocardial infarc-
tion. Surgical specimens were: post-stenotic aortic root dilatation;
aspecific atherosclerosis of aorta; degenerative aortic dilatation;
bicuspid aortic valve malformation without cystic media necrosis.
Patients and control aortic samples were paraffin-embedded and
Inflammation Aggravates Marfan Syndrome
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32963
immunohistochemical staining was performed using widely used
and established antibodies, detecting CD+4, CD8+ and CD68+
markers. Cells were counted in the aortic media and adventitia.
Statistical analysis and functional annotation
Hierarchical clustering of microarray data was performed in R
program using ‘‘stats’’ package. Differences in clinical features
between patients in different clusters were investigated using
ANOVA and Chi-square tests in R program using ‘‘stats’’
package. T-test was used to investigate cytokine differences
between groups of patients in ‘‘stats’’ package. Differences in gene
expression between patients were analyzed using univariate linear
regression analysis with permutation testing in Significance
Analysis of Microarrays R package in R program [32]. Only
genes with a q-value (FDR) of 0 were considered significant. Gene
functions presented in tables were searched manually in NCBI
databases; only direct experimental evidence or associations from
genome wide association studies were included in functional
annotation reported in tables.
Supporting Information
Figure S1 Heatmap of the hierarchical clustering of 55 MFS
patients based on similar gene expression patterns. Four distinct
patients’ clusters of 16, 27, one and 11 patients were defined.
Approximately 1800 genes differed significantly (FDR=0%,
minimal fold change = 2) between the clusters. However, clinical
significance of these findings seems to be limited as no differences
were found in disease severity between the patients’ clusters.
(DOC)
Figure S2 Plots of the correlation of (A) Z-score (aortic root
diameter corrected for age, sex and Body Surface Area) and (B)
aortic root dilatation rate with TGF-b levels in plasma of MFS
patients. None of the two parameters of progressiveness of aortic
disease correlated with TGF-b (p = 0.2 and 1 respectively).
(DOC)
Table S1 Plasma levels of TGF-b, CRP, and cytokines in MFS
patients. Note: A – mean levels of cytokines in plasma of patients.
B – mean level of CRP (mg/L) in patients serum.
(DOC)
Table S2 Genes differentially expressed in patients with and
without ectopia lentis. Note: A- Fold change, a ratio between
mean expression levels in patients with ectopia lentis and ones
without it.
(DOC)
Table S3 Up-regulated genes in patients with pectus deformities.
Note: A- FC exc –ratio between mean expression levels of patients
with severe pectus excavatum and patients without pectus
deformity. B- FC car- ratio between mean expression levels of
patients with pectus carinatum and patients without pectus
deformity.
(DOC)
Table S4 Down-regulated genes in patients with pectus
deformities. Note: A-FC exc –ratio between mean expression
levels of patients with severe pectus excavatum and patients
without pectus deformity. B- FC car- ratio between mean
expression levels of patients with pectus carinatum and patients
without pectus deformity.
(DOC)
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